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Abstract
T cells play a central role in immune-homeostasis; specifically in the induction of antigen-specific adaptive
immunity against pathogens and mutated self with immunological memory. The thymus is the unique organ
where T cells are generated. In this review, first the complex structures and functions of various thymic
microcompartments are briefly discussed to identify critical engineering targets for regeneration of thymic functions
in vitro and in vivo. Then the biomimetic regenerative engineering approaches are reviewed in three categories: 1)
reconstruction of 3-D thymic architecture, 2) cellular engineering, and 3) biomaterials-based artificial presentation of
critical biomolecules. For each engineering approach, remaining challenges and clinical opportunities are also
identified and discussed.
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Background
The thymus is the primary lymphoid organ that is
uniquely responsible for T cell lymphopoiesis. It has long
been established that the absence or malfunction of a
thymus directly causes severe immunodeficiency due to
the withdrawal of healthy peripheral T cells [1, 2]. Over
the last few decades, much progress has been made in
understanding the cellular and molecular details of how
each thymic compartment collaborates to support the
development of “healthy” T cell populations. The
“healthy” T cells need to be able to distinguish “self”
from “foreign” in a very specific, sensitive, and rapid
manner to endow immunological protection from invad-
ing pathogens or malignant mutations. Considering this
daunting task, various thymic compartments must be
exceptionally well-orchestrated to support the develop-
ment of functional T cells. Similar to other efforts in re-
generative engineering of various complex organs,
regeneration of thymic functions must be achieved based
on the understanding of anatomy and functions of each
thymic compartment. Therefore, our current under-
standing on the functional components of the thymus
will first be discussed from the perspective of regenera-
tive engineering. Then, recent engineering efforts to re-
capitulate each thymic compartment will be reviewed.
From a clinical point of view, regenerative engineering
of the thymus could be intended for multiple purposes
including 1) support of in-vivo development of endogen-
ous T cells, 2) robust generation of T cell precursors
from readily available autologous or allo-matched donor
stem cells, 3) induction of donor-specific immune toler-
ance to allografts [3], 4) in-vivo/in-vitro generation of
antigen-specific T cells, and 5) simple in-vitro culture
models to study T cell lymphopoiesis. Thus, we will dis-
cuss the engineering approaches of each thymic com-
partment along with the lines of thymic functions it
could recreate, the relevant applications as well as the
associated challenges.
Review
1. Anatomy and functional compartments of the thymus
The development of T cells (Fig. 1) starts by
recruitment of bone-marrow-derived early T cell
progenitor cells into the thymus. This initial cell
population differentiates into serially distinctive
stages while migrating through discrete compart-
ments of the thymus until becoming mature T cells
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that return to the periphery. The collective know-
ledge on these anatomical regions regarding the se-
quential development of T cells in adult and
embryonic thymus has been reviewed elsewhere [4,
5]. T cells in each developmental stage mature into
the next step by interacting with the special cellular
components in the region and migrate into the next
region in concerted molecular signals given by
chemokines, cytokines, adhesion molecules, lympho-
toxins, and other developmental signals [6].
For regenerative engineering, it is beneficial to
consider the thymic structure as an assembly line
with serial modular compartments. First, a thymus
is divided into two, the cortex and medulla. The
early T cell progenitors enter the thymus near the
cortico-medullary junction as CD4-CD8-double-
negative (DN) cells. The DN stages are further
subdivided based on the cell-surface expression of
CD25 and CD44 (or CD117) [7]. The starting DN1
populations progress into DN2 and DN3 stages as
they migrate outward, through the cortex, while
interacting with cortical stromal cells, including
thymic epithelial cells (cTECs) and mesenchymal
fibroblasts. DN thymocytes further develop into
CD4 + CD8+ double-positive (DP) cells, which
migrate inward, back to the cortico-medullary
junction, maintaining rich contacts with cTECs.
Finally, mature CD4 + CD8- or CD4-CD8+ single-
positive (SP) T cells migrate into the medulla, inter-
act with medullary TECs (mTECs) and/or dendritic
cells, until they finally egress the thymus into the
peripheral blood.
Throughout these developmental stages, the critical
signals are provided by regional cellular and
molecular components, which can be categorized
into three types: 1) signals for T cell lineage
commitment; 2) antigen recognition signals; and 3)
cues for migration. These molecular signals are
often closely related to each other with mutual
causalities. First, the signals for lymphocyte stem/
progenitor cells to develop into the T cell lineage
are critical in the initial DN developmental steps,
and produce universal effects in all thymocyte
progenitor cells. However, the second signal that
originates from antigen-recognition selectively
affects the survival and developmental fate of a T
cell clone with a unique T cell receptor (TCR). The
special antigen recognition capacity of a T cell is
conferred by the intricate affinity between TCR and
peptide-major histocompatibility complex (pMHC).
DP T cells actively survey the pMHC molecules
expressed on the surface of cTECs. Only those T
Fig. 1 T cell development in thymic microcompartments. Bone-marrow derived hematopoietic stem/progenitor cells (green) enter the thymus
through post-capillary venules and differentiate into T lineage cells (orange). Double negative (DN) thymocytes migrate outward in cortex (light blue
region) as they interact with cortical TECs (cTECs, pink) and receive Notch signaling. DP thymocytes undergo positive selection as they migrate back to
cortico-medullary junction interacting with pMHC expressed on cTECs. Positively selected thymocytes migrate into medulla (dark blue). SP thymocytes
undergo the majority of negative selection within medulla by being tested for reactivity to tissue-restricted self-antigens expressed by medullary TECs
(mTECs, purple) or dendritic cells (DCs, yellow). Mature SP thymocytes reciprocally promote maturation of mTECs by LTβR signaling. Mature T cells exit
the thymus via blood or lymph. Modified from ref. [5] and [60]
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cells that can recognize the self-antigens receive
survival signals and develop further (positive
selection). But once these positively-selected T cells
reach the medulla as SP T cells, they will interact
with mTECs and DCs, and the T cells that
recognize tissue-specific self-antigens with “higher”
affinities undergo apoptosis (negative selection) to
prevent autoimmunity. Lastly, there are concerted
molecular mechanisms that allow developing T cells
to migrate between regional compartments, one
after another, which involves various chemokines
and adhesion molecules. Excellent reviews that
further detail the molecular interactions and devel-
opmental signaling events can be found elsewhere
[8, 9]. It should be noted that the cellular communi-
cations between developing T cells and thymic
stroma are reciprocal, i.e. while developing T cells
receive above-mentioned complex molecular signals,
they also provide critical signals to the thymic
stromal cells for their survival and function [10, 11].
Even though the majority of previous studies on T
cell development were performed on αβ T cells,
namely either CD4+ helper T cells or CD8+
cytotoxic T cells, knowledge on the ability of thymic
microenvironments to support the development of
other thymocyte lineages, such as NKT cells [12–14],
γδ T cells [15–20], and Foxp3 + CD4 + CD25+
regulatory T (Treg) cells [21–23] is also accumulating.
All of these studies likewise provide significant
insights on engineering those special niches for
regenerative purposes.
2. Engineering for regeneration of thymic functions
In order to recapitulate the unique structures and
functions of the thymus and its compartments,
efforts have been made in three directions: 1)
reconstruction of 3-dimensional (3-D) thymic stro-
mal cells (TSCs) network, 2) cellular engineering,
and 3) artificial presentation of developmental signals
(Table 1).
a. Reconstruction of 3-D network architecture of TSCs
Unlike B-cell development, which can be re-
capitulated in vitro by co-culture of
hematopoietic stem/progenitor cells on a 2-
dimensional (2-D) layer of bone-marrow-
derived stromal cell lines [24], T cell develop-
ment cannot be successfully reproduced by
using TECs cultured on 2-D environments.
Instead, TECs cultured on a 2-D environment
lose the expression of characteristic genes
[25], and differentiate into skin cells or
express markers of other terminally differenti-
ated epithelial cells [26]. Naturally, TECs in
the thymus form a very unique, sponge-like
3-D network structure [11], which might be
critical for rich crosstalk between developing
T cells and thymic stromal cells as well as
migration of developing T cells.
Even before the full molecular details of how 2-
D vs. 3-D environments affect the gene expres-
sion of TECs were elucidated, fetal thymic
organ culture (FTOC) was introduced as a sim-
ple method to culture TECs in 3-D and achieve
in-vitro T cell development [27–30]. FTOC has
served as the main in-vitro culture platform to
study T-cell development, and various modifica-
tions have also been introduced. For example,
Jenkinson et al. made use of deoxyguanosine,
which is selectively toxic to mature T cells, to
deplete the endogenous T cells from FTOC
while maintaining the surviving stromal ele-
ments [31]. The “emptied” FTOC can be recolo-
nized by stromal and lymphoid cells of different
haplotypes, and has become a great platform to
study T cell tolerance and MHC restriction in
vitro. Meanwhile, grafting fetal thymus tissue in
an ectopic location of an immune-deficient
murine model has provided means to study
thymopoiesis in vivo. The most established
example is the grafting of fetal thymus tissue
under the kidney capsule [32]. The neovascular-
ization within the grafted tissue allows for con-
tinuous entry of T cell progenitors and further
development of the grafted tissue to an ectopic,
functional thymus. It was also shown that co-
implantation of human fetal liver and human
fetal thymus under the kidney capsule could
establish humanized mouse models [33] to
study human T lymphopoiesis with or without
concurrent intravenous administration of human
hematopoietic stem progenitor cells [34, 35].
Ectopic grafts of murine fetal thymus lobes were
also achieved by a tissue engineering method-
ology named the mouse chamber (MC) model
[36]. In this model, murine thymus lobes and
extracellular matrix containing growth factors are
enclosed together within a silicone tube which is
then implanted around the epigastric vessels of
the groin vascular bed. The murine fetal thymus
tissue was successfully engrafted and vascularized
in the chamber, and supported de novo gener-
ation of functional T cells [36].
Instead of using an intact fetal thymus tissue, a
single cell suspension of thymic stroma can be
prepared by enzymatic degradation of
deoxyguanosine-treated fetal thymic lobes.
When thymic stromal cells are reaggregated to-
gether with HSC-derived T progenitor cells and
cultured in a hanging drop or on culture sponge
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(named as reaggregate thymus organ culture,
RTOC), it also supports T cell development in
vitro [37, 38]. More recently, Chung et al. re-
ported that EPCAM+CD45-CD105- TECs and
CD45-EPCAM+CD105+ thymic mesenchyme
(TM)-enriched populations can be separately
isolated from postnatal human thymus using
specific culture conditions, and used for RTOC
with human cord blood-derived CD34+
hematopoietic stem and progenitor cells
(HSPCs) [39]. This aggregate culture supported
T cell generation to a certain degree in vitro as
well as in vivo following inguinal implantation
in immune deficient mice. When TM engi-
neered to express vascular endothelial growth
factor via lentiviral transfection was employed,
the implanted reaggregates showed enhance-
ment in size and T cell production.
3-D culture of thymic stromal cells was also
enabled by using artificially engineered scaffolds.
A confluent layer of murine thymic stroma was
generated on top of tantalum-coated reticulated
structure of carbon matrices, which showed
syngeneic or xenogeneic support for generation
of functional murine [40] or human [41] T cells
in vitro upon co-culture of thymus- or bone
marrow-derived hematopoietic progenitor cells.
Among the various functional supports
provided by each cellular component in the
thymus, mTECs are responsible for expressing a
host of tissue-restricted antigens, termed “pro-
miscuous gene expression”, which is critical for
the negative selection of self-reacting T cells
[42]. However, expression of the critical molecu-
lar components for mTECs functional features,
such as Aire and transcription factor forkhead
box N1 (FoxN1), are known to be downregulated
upon 2-D culture of TECs [26, 43]. Motivated by
phenotypic similarities between mTECs and ker-
atinocytes, Pinto et al. cultured mTECs on top of
a 3-D co-culture system that previously had
shown in-vitro skin development [44]. mTECs
Table 1 Characteristic features, applications, advantages, and limitations of engineering approaches for T lymphopoesis
Engineering approaches Applications Advantages (+) and limitations (−) Representative
and notable
references
1) Reconstruction of TSC’s 3-D network
• Fetal thymic organ culture (FTOC)
• Reaggregate thymus organ culture
(RTOC)
• Artificial scaffolds
• Decellularized thymic scaffolds
• To study T cell tolerance and MHC
restriction in vitro
• To study thymopoiesis in vivo upon grafting
into an ectopic locations of athymic mice
• Simple and straightforward design
(+)
• Absolute dependency on biopsy
and isolation of thymus or thymic
cells (−)
• Limited culture sizes of 3-D plat-
forms (−)
• Limited number of T cells that can
be generated in vitro (−)










• Differentiation of stem cells into TSCs
• Genetic introduction of effector
molecules that define TSC functions to
cell lines or somatic cells
• Cell reprogramming
• To use human pluripotent stem cells for
regeneration of thymus or induction of
immune tolerance
• To generate T cell precursors and functional
T cells using robust 2-D culture platforms in
vitro
• Use of clinically relevant,
endogenous stem cell sources (+)
• Use of readily available 2-D culture
platforms for recapitulation of T lym-
phopoesis in vitro (+)
• Potential xenogenic cross-
contamination (OP9-DL1) (−)
• Ineffective positive selection of CD4
+ T cells (OP9-DL1) (−)
• Need for complex genetic
modifications and related risk of viral
contamination (−)
• mESC to TEPC
[50, 51]
• hESC to TEC [53,
54]
• OP9-DL1 [59]






3) Biomaterials-driven artificial presentation of developmental signaling molecules
• Plate- or bead-bound Notch ligands for
differentiation of T precursors from vari-
ous stem cells
• Use of pMHC tetramer to induce
antigen specificity on developing T cells
• To generate T precursors from various stem
cells in vitro, which later can be employed in
adoptive cell therapies.
• To induce or selectively expand antigen-
specific T cells
• Potential realization of purely
biomaterial-based T lymphopoesis ex
vivo (+)
• Requirement for expensive
recombinant proteins (−)
• Generation of potentially self-
reactive T cells due to lack of nega-
tive selection (−)
• Limited T cell expansion (−)
• Notch ligands
[74, 75, 77, 79]
• pMHC tetramer
[80, 81]
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proliferated and sustained the expression of Aire
and FoxN1 when they were cultured on a 3-D
non-woven fibrous scaffold seeded with skin-
derived dermal fibroblasts in fibrin gel. Even
though this culture system showed a new possibil-
ity to recapitulate promiscuous gene expression by
mTECs in vitro, an emulation of functional nega-
tive selection in de novo T cell regeneration was
not attempted.
Recently, a more robust reconstruction of
thymus organoids was achieved using
decellularized thymic scaffolds [45]. The
acellular scaffold can be prepared by a
detergent-perfusion based method that enables
the clearance of cellular components while
retaining the original 3-D architecture and
extracellular matrix (ECM) of various organs
[46–48]. Upon repopulating the 3-D acellular
thymic scaffold with thymic stromal cells (TSCs)
and BM derived Lin- progenitor cells, various
components of TSCs including TECs, endothelial
cells, and thymic fibroblasts, remained viable for
more than 3 weeks, and supported in vitro T cell
generation. When transplanted into athymic
nude mice, these thymus organoids effectively
function to support induction of T cell-
dependent humoral and cellular immunity.
Moreover, induction of tolerance to allograft was
achieved by employing thymus organoid con-
structed with mixture of TECs derived from the
donor and the recipient mice.
Engineering approaches mentioned above have
proven to be versatile and useful in fundamental
research as well as potential clinical applications
in vitro and in vivo. However, the universal
need for isolation of thymic stroma from the
patient and the limited size and number of cells
generated by in-vitro methods make it difficult
to apply these methods more widely.
b. Cellular Engineering Approaches
For robust regeneration of thymic functions,
each cellular component is an interesting target
for cellular engineering. Historically, two lines
of activity have yielded prominent progresses: 1)
differentiation of stem cells into various thymic
stromal cells, 2) genetic introduction of key
molecules that define thymic functions [6] or
transcription factors [49] to cell lines or other
somatic cells. Both approaches could potentially
negate the absolute dependency on TSCs
isolated from thymus biopsies and/or need of
complex 3-D culture condition.
Mouse embryonic stem cells (mESC) were
successfully differentiated to thymic epithelial
progenitor cells (TEPCs), which could further
differentiate to both cortical and medullary
TECs [50]. When placed in vivo, these mESC-
derived TECs could support thymopoiesis upon
either syngeneic [50] or allogenic [51] bone
marrow transplant. Moreover, mESC-derived
TEC-treated mice developed tolerance against
host and mESCs upon allo-BM transplant [51].
Using a separate method, Inami et al. success-
fully differentiated induced pluripotent stem
cells (iPSCs) to TEPC and mTEC phenotypes
[52]. More recently, functional TECs were also
generated from human embryonic stem cells
(hESCs) by precise regulation of TGFb, BMP4,
RA, Wnt, Shh, and FGF signaling [53], or by
sequential regulation of Activin, retinoic acid,
BMP, and WNT signals [54]. These studies
made important progress towards employing
human pluripotent stem cells for thymus trans-
plantation, particularly for clinical purposes
such as induction of tolerance to stem-cell-
derived cell-therapeutics, or restoration of
senescing thymic functions.
As mentioned above, 3-D culture condition had
been regarded as mandatory for TEC to support
T cell development in vitro. In comparison,
early hematopoiesis and B cell lymphopoiesis
can be well supported by a monolayer (2-D)
culture of bone-marrow-derived stromal cell
line such as OP9 [55, 56]. This bone marrow
stromal cell line was derived from OP/OP
mice that are deficient in macrophage
colony-stimulating factor (MCSF), which in
turn contributed to the ability of OP9 cells to
preferentially support differentiation of HSCs
to B cells over myeloid cells. Inspired by the
two separate findings that 1) Notch signaling
plays important roles at various stages of T
cell development [57, 58], and 2) OP9 cells
constitutively express both members of
jagged-gene family but fail to support T cell
generation, OP9 cells were engineered to ex-
press another Notch ligand, delta-like 1
(OP9-DL1) by retroviral transduction [59]. In-
deed, the 2-D monolayer of OP9-DL1 cells could
support T-cell differentiation from HSCs, includ-
ing the generation of DP and CD8+ SP cells [59,
60], thus changing the paradigm of 3-D require-
ments for in-vitro T lymphopoiesis. Later, it was
proven that the TSCs cultured in 2-D monolayer
indeed lose the expression of Notch ligands,
delta-like ligand (DLL)1 and DLL4, which has a
direct causal effect on the loss of ability to sup-
port T lymphopoiesis [61]. It is noteworthy that
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ectopic re-expression of Notch ligands was suffi-
cient for the 2-D cultured TSCs to support T cell
generation.
Despite the robust induction of functional T cells
from multiple sources of stem cells [62–65],
OP9-DL1 co-culture has some limitations. One
of the main drawbacks is the lack of MHC class
II or CD1d expression in OP9 cells, which co-
nsequently hampers their support for the positive
selection of CD4+ T cells and NKT cells, respect-
ively [60]. In addition, OP9 cells do not express a
host of tissue-restricted antigens like mTECs,
thus proper negative selection of the self-reactive
TCR repertoire is lacking. Nevertheless, function-
ally mature T cells including CD4+ and CD8+
were obtained from HSCs by OP9-DL1 co-
culture systems, which indicate that some level of
positive selection is induced by interaction be-
tween T precursor cells [66].
A couple of exciting strategies were developed
to utilize the OP9-DL1 system for clinical appli-
cations by avoiding the need of rigorous selec-
tion processes in vitro. First, OP9-DL1 co-
culture system was employed to robustly gener-
ate T cell precursors from HSCs. The generated
T precursors were adoptively transferred to
lethally-irradiated allogeneic recipient mice to-
gether upon bone-marrow transplantation.
Adoptively transferred T-cell precursors could
give rise to enhanced T-cell dependent immunity
against infection and significant graft-versus-
tumor (GVT) activity but without graft-versus-
host disease (GVHD) [67]. Second, two separate
studies have utilized OP9-DL1 for generation of
cytotoxic T cells from human HSCs genetically
modified to express tumor- or virus- specific
TCRs, which negated the need of TCR selection
processes [68, 69].
A human TEC line expressing human leukocyte
antigens (HLAs) was genetically engineered to
overexpress murine DLL1 as an alternative
strategy to utilize both Notch signaling and
interactions between TCRs and pMHC
molecules [70]. This TEC-DL1 line promoted
generation of DP T cells from BM- and CB-
derived hematopoietic precursor cells (HPCs).
However, how the presence of HLAs contrib-
uted in this de novo generation of T-lineage
committed cells (such as positive selection) still
remains to be studied.
Instead of genetically introducing individual key
effector molecules that define thymic functions,
Bredenkamp et al. reprogrammed primary
mouse embryonic fibroblasts into functional
TECs by forced expression of the transcription
factor FoxN1, which is critically required for
development of TECs [49]. On a regular 2-D
culture platform, FoxN1-induced TECs sup-
ported efficient development of CD8+ as well as
CD4+ T cells in vitro, owing to their capacity to
express both MHC class I and II. When the cel-
lular aggregates of these FoxN1-induced TECs,
thymocytes, and TM cells are grafted under the
kidney capsule, they develop into spatially orga-
nized cortex and medulla of a fully functional
thymus unit. Despite some practical hurdles that
prevent direct application of a similar technology
to human patients, this cell reprogramming
method shows tremendous potential towards
patient-specific custom-designed T cell therapies.
In terms of clinical applications, neither using
patient derived TSCs nor employing OP9-DL1
cells are perfectly ideal for the derivation of T
cells from stem cells. Thymic biopsy or an
equivalently invasive procedure is required to
acquire TSCs, and the number of TSCs that you
can get is normally limited. Using xenogenic
materials such as OP9 cells is not ideal due to
potential cross-contamination, not to mention
other limitations considered above. Clark et al.
reported that functional human T cells can be
induced from HPCs by co-culturing them on a
tantalum-coated reticulated carbon matrix
seeded with human-skin derived fibroblasts and
keratinocytes, replacing conventionally
employed TSCs and TECs, respectively [71].
Moreover, de-novo generated T cells possessed
a diverse TCR repertoire, and were functionally
mature but tolerant to self-MHC; this strongly
indicates successful performance of positive and
negative selection processes in vitro. However,
the reproducibility of some of these exciting
findings have been questioned by others [72], so
a certain reconciliation within the field is
awaiting.
c. Biomaterials-driven artificial presentation of signaling
molecules
As shown above, Notch signaling provided by
Notch ligands, DLL1 and DLL4, has been
identified as the critical molecular components
for induction of T cell-lineage commitment
from stem cells [73]. Therefore, there is a po-
tential to recapitulate effective T lymphopoiesis
by induction of proper Notch signaling using
artificial presentation of Notch ligands.
Towards this goal, some very important studies
have provided background knowledge and
engineering strategy. First, it was shown that
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the extracellular domain of Notch ligands need
to be immobilized onto a surface to effectively
induce Notch signaling, while soluble
counterparts bind to Notch receptor without
signaling induction, thus they are inhibitory to
Notch function [74]. Relatively low surface
densities of Delta-1 support differentiation of
early T cell precursors as well as B cell precur-
sors, while higher densities of Delta-1 suppress
B cell-lineage commitment [75]. The two Notch
ligands, DLL1 and DLL4, both of which are crit-
ical for development of T cell lineage, perform
differently in terms of inhibition of B and
myeloid-specific transcription factors at equiva-
lent lower density limits [73]. In broader sense,
the surface density of Notch ligands becomes
an important determinant in regulating
hematopoietic cell-fate outcomes, affecting ex-
vivo differentiation as well as in-vivo marrow
repopulating ability of cord blood [76].
It was shown that plate-bound Delta-1 could
expand and induce T cell precursors from either
human CD34 + CD38- cord blood cells [77] or
lin-Sca-1 + c-kit + (LSK) murine HSCs [78],
which resulted in enhanced T cell thymic re-
constitution upon adoptive transfer of these
cells. Instead of plate-bound form and a defined
media, Taqvi et al. utilized DLL4-functionalized
microbeads and insert co-culture on top of an
OP9 cell monolayer to successfully generate
Thy1.2+ early T cells from LSK HSCs without
direct OP9 stromal cell contact [79].
It is noteworthy that in these culture conditions
with artificially presented Notch ligands, proper
cytokine mixture needs to be supplemented
either by defined composition of recombinant
components or by conditioned media obtained
by stromal cell culture. And despite the
successful generation of early T cells mentioned
above, mature and functional SP T cells have
hardly been achieved by these biomaterial-based
in-vitro culture systems.
The other critical molecular components
provided by thymic stroma to developing T cells
are pMHC molecules. Lin et al. demonstrated
that both thymus-derived DP thymocytes and
murine ESC-derived cells can be differentiated
into CD8+ SP T cells by using MHC tetramers
during differentiation culture. The resulting
CD8+ T cells showed significant cytotoxic T
lymphocytes activity against target cells loaded
with the same antigen as used in the culture
[80]. More recently, a similar strategy was also
applied to human umbilical cord blood derived
CD34 + CD38-/low human HSCs [81]. CD1a +
CD7+ and DP T cells were differentiated from
human HSCs using plate-bound DLL1, and sub-
sequently cultured with tetramers of HLA-
A*0201 restricted cytomegalovirus (CMV) or
influenza epitopes. Again, the resulting CD8+
SP T cells cultured with each antigen showed
in-vitro cytolytic functionality against corre-
sponding peptide-loaded target cells in an
antigen-specific manner [81]. Even though such
in-vitro generation of functional, antigen-specific
T cells from clinically relevant cell sources could
eventually provide a new opportunity in adoptive
transfer immunotherapies, there remain some
important questions: How specific are the new
TCRs? Are these new TCRs self-reactive? Can
these antigen-specific T cells be significantly
expanded in number? Efforts to answer to these
questions and further engineering strategies to
properly incorporate positive and negative
selection processes into in-vitro T lymphopoiesis
would warrant a safer, more versatile and robust
clinical applicability.
Conclusions
There are great and growing needs for engineering ap-
proaches to regenerate T lymphopoieis in vitro as well
as in vivo. In many developed countries, the demo-
graphic structure is getting older and reverting age-
related thymic atrophy is becoming more important. In
addition to providing means to cure the thymic atrophy
caused by diseases such as DiGeorge syndrome [82], se-
vere combined immunodeficiency syndrome (SCID) [83]
and various infections [84, 85], de-novo T cell generation
from various stem and progenitor cells has a great po-
tential in T cell adoptive transfer immunotherapy for nu-
merous cancers, which recently attracted huge interests
from academia as well as the pharmaceutical industry
[86–88]. In order to translate its immense clinical prom-
ise and rapid scientific progress into clinics, adoptive T
cell transfer therapy needs to find scalable technologies
for providing functional T cells from HLA-matched,
readily available sources. As discussed in this review,
each engineering approach for T cell generation has its
own advantages and disadvantages (Table 1), and must
find its most appropriate use in diverse applications.
Nevertheless, development of more robust engineering
approaches to recapitulate full arrays of thymic func-
tions, namely, T lineage commitment, and rigorous posi-
tive/negative selections in a clinically scalable fashion is
an ongoing task.
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